ReviewInternal and emergency medicine2026
CGRP-targeted therapies for migraine and the risk of infection.
Review in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of CGRP-pathway inhibitors has markedly changed the management of migraine, providing effective and well-tolerated options for many patients who were previously difficult to treat. Their overall safety profile appears favorable; however, emerging observations have prompted questions regarding possible infectious complications related to CGRP blockade. This review summarizes the available evidence on infection risk associated with CGRP-targeted therapies, integrating data from randomized clinical trials, post-marketing pharmacovigilance, and experimental immunological studies. While no consistent signal of increased infections has been observed in controlled trials, real-world data and mechanistic considerations suggest that interference with CGRP pathways might, under certain conditions, influence host immune defense. Although infections remain uncommon, awareness of this potential risk is important, particularly in patients with pre-existing immunological frailty or multiple comorbidities. Ongoing surveillance and focused clinical studies will be essential to clarify these aspects and guide safe, long-term use of CGRP inhibitors in everyday clinical practice.
Indexed as
Identifiers
42201619What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.